In its continued bid to waylay the launch of MSN Pharmaceuticals’ proposed Entresto generic, Novartis has told a federal ...

Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate ...

Novartis admitted the email broke several rules set out in the U.K. marketing code. In a long response to the PMCPA, the ...

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.

The next big test is whether using Pluvicto can delay the advancement of prostate cancer enough to delay chemical castration, ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

The main point of investing for the long term is to make money. But more than that, you probably want to see it ...

Regulus Therapeutics Inc.‘s up to $1.7 billion sale to Novartis AG was flawed, primarily benefiting board members and executives who have large amounts of illiquid shares instead of public ...

Regulus filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC, which includes, among other things, the recommendation of Regulus’s board of directors that Regulus’s stockholders ...

Get the detailed quarterly/annual income statement for NOVARTIS AG N (NOT.DE). Find out the revenue, expenses and profit or loss over the last fiscal year.